B-cell Precursor Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Precursor Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating subcutaneous blinatumomab in children with relapsed/refractory and MRD-positive B-cell precursor acute…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL [Phase 1, Phase 2]
The document provides a clinical trial update for a study evaluating subcutaneous blinatumomab in participants with relapsed/refractory and …
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) [Phase 2]
A Phase 2 clinical trial update describing blinatumomab administration in Chinese pediatric participants with relapsed/refractory B-cell pre…
-
EMA approval · 2025-11-06EMA Authorised: Kymriah (tisagenlecleucel) — Novartis Europharm Limited
The EMA authorised Kymriah (tisagenlecleucel) for additional indications in precursor B-cell lymphoblastic leukemia/lymphoma and diffuse lar…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL [Phase 1]
HQP1351 is being investigated in a Phase 1 trial for patients with refractory chronic myeloid leukemia and Philadelphia chromosome-positive …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2025-10-21FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for BLINCYTO (blinatumomab) submitted by Amgen to update the labeling. The change reflects an expand…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) [Phase 1, Phase 2]
This document describes a Phase 1/2 trial evaluating the combination of venetoclax with blinatumomab in adults with relapsed or refractory B…
-
CLINICAL_TRIALS research · 2025-05-23Clinical Trial Update: Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 [Phase 1]
Phase 1 study of autologous CD19-targeted CAR-T cells for precursor B-cell acute lymphoblastic leukemia. The trial status is active but not …
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) [Phase 4]
A Phase 4 feasibility trial evaluating outpatient administration of blinatumomab in patients with minimal residual disease in B-cell precurs…
-
FDA approval · 2025-04-29FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for BLINCYTO (blinatumomab) from Amgen, Inc., updating labeling and/or expanding the approved in…
-
CLINICAL_TRIALS research · 2025-01-08Clinical Trial Update: NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL [NA]
This document describes a planned clinical trial to evaluate minimal residual disease-guided treatment with blinatumomab for pediatric B cel…
-
FDA approval · 2019-04-18FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for BLINCYTO (blinatumomab) submitted by Amgen, signaling an update to labeling and/or indicatio…
-
CLINICAL_TRIALS withdrawal · 2018-07-26Clinical Trial Update: Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) [Phase 2]
A Phase 2 trial evaluating daratumumab for relapsed/refractory B-cell or T-cell precursor acute lymphoblastic leukemia has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-07-20Clinical Trial Update: Acute Lymphoblastic Leukemia Registry at Asan Medical Center
The Acute Lymphoblastic Leukemia Registry trial at Asan Medical Center has been terminated.
-
FDA approval · 2014-12-03FDA Approved: BLINCYTO — Original Application (Amgen, Inc)
The FDA approved BLINCYTO (blinatumomab) from Amgen as an original application. It is a novel bispecific T-cell engager indicated for relaps…
-
CLINICAL_TRIALS research · 2012-10-24Clinical Trial Update: Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. [Phase 1, Phase 2]
Terminated Phase 1/2 pharmacokinetic study of forodesine in children with relapsed or refractory T-cell or B-cell precursor acute lymphoblas…